ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BBC Virtus LifeSci Biotech Clinical Trials ETF

25.2568
-0.3706 (-1.45%)
Apr 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 37
Bid Price
Ask Price
News -
Day High 25.65

Low
16.88

52 Week Range

High
31.99

Day Low 25.65
Company Name Etf Ticker Symbol Market Type
Virtus LifeSci Biotech Clinical Trials ETF BBC AMEX Exchange Traded Fund
  Price Change Change Percent Etf Price Last Traded
-0.3706 -1.45% 25.2568 20:00:00
Open Price Low Price High Price Close Price Prev Close
25.65 25.65 25.65 25.2568 25.6274
Trades Volume Avg Volume 52 Week Range
14 37 - 16.88 - 31.99
Last Trade Time Type Quantity Etf Price Currency
20:00:00 100  25.2568 USD

Virtus LifeSci Biotech Clinical Trials ETF Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
11.53M 450.00k - 132k -4.06M -9.03 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Virtus LifeSci Biotech C...

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BBC Message Board. Create One! See More Posts on BBC Message Board See More Message Board Posts

BBC Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week26.2526.2524.5725.24958-0.9932-3.78%
1 Month28.6129.2824.5727.523,317-3.35-11.72%
3 Months25.2731.9924.5728.634,361-0.0132-0.05%
6 Months17.3031.9916.8826.033,2467.9645.99%
1 Year23.7231.9916.8825.172,2411.546.48%
3 Years49.9452.4116.8832.103,386-24.68-49.43%
5 Years28.6262.6016.8837.679,216-3.36-11.75%

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

Your Recent History

Delayed Upgrade Clock